Viewing Study NCT01647659

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:49 PM
Ignite Modification Date: 2025-12-26 @ 12:24 AM
Study NCT ID: NCT01647659
Status: COMPLETED
Last Update Posted: 2017-11-13
First Post: 2012-07-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None MEK inhibitor GSK1120212 View
None pharmacokinetics View
None powder for oral solution View
None Solid Tumors View
None pediatric formulation View